All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Miricorilant
Therapeutic Area: Nutrition and Weight Loss Product Name: CORT118335
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
GRATITUDE I, Corcept’s first Phase 2 trial of miricorilant in APIWG, continues to enroll patients with schizophrenia and recent weight gain.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GDD3898
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Maxim Merchant Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing March 03, 2020
Details:
The financing will support the development of its lead therapeutic candidate GDD3898.